H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth
H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.
How this was made
The 30-second read
Why it matters
The buy rating and $20 target could attract short‑term buying pressure, especially in after‑hours trading.
Market read
Earnings beat and analyst upgrade provide a fresh catalyst for VNDA, offering a potential short‑term trade.
What to watch
Potential risks from upcoming FDA approvals and the need for sustained sales growth.
Background
Vanda Pharmaceuticals reported Q3 2026 results with net sales of $69.8M and a loss narrower than expected, prompting an analyst upgrade.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $20 price target on Vanda after its Q3 2026 earnings beat and narrowed loss.
likely upward as investors price in the buy rating and better-than-expected loss.
The company posted a loss of $0.37 vs. $0.68 expected and revenue slightly above forecasts, prompting a fresh buy recommendation.
Market effects
Positive earnings may lift other small-cap pharma stocks.
US biotech sector could see modest gains.
Limited to US-listed biotech investors.
Counterpoint
The earnings beat is modest and the stock remains far below its 52‑week high; upside may be limited.
Key entities
- CompanyVanda Pharmaceuticals
US-listed biotech firm (NASDAQ:VNDA).
- AnalystH.C. Wainwright
Equity research firm that issued the Buy rating.
